
Shin splints can literally become an athlete’s Achilles heel. This
very common symptom, suffered mainly by athletes, can be triggered be
several conditions. No matter precisely what the reason, the outcome can
be unbearable pain and in most cases extended months of recovery and
rest. Using a revolutionary new Platelet-Rich Plasma (PRP) therapy, Dr.
Bill J. Releford can substantially reduce the painful manifestations of
shin splints, speed the therapeutic process, and get athletes on their
feet once again – rapidly.
“An athlete came to see me after suffering from painful shin splints
for
more than a year. He spent several months on the sidelines, unable
to enter in competition,” said Dr. Releford. “After just one series of
PRP injections, the sprinter was back on the track, without any pain,
and put in a solid performance.”
A doctor of podiatric medicine, Dr. Releford is the medical director
and founder of The Releford Foot and Ankle Institute and Beverly Hills
PRP. He finds PRP injections beneficial in his practice and uses them to
treat sports-related and orthopedic injuries, and many other
conditions.
PRP therapy is non-surgical. By injecting a small, concentrated
amount of a patient’s own blood into injured tissue, PRP therapy
“supercharges” the healing process and reduces or even eliminates pain.
About Platelet-Rich Plasma Therapy
PRP therapy is an innovative, non-surgical approach that uses
healing components derived from a small, concentrated amount of a
patient’s own blood. Injected into damaged tissue, PRP therapy has the
potential to “supercharge” the healing process. PRP has been
successfully used in orthopedics and sports medicine to treat joint and
tendon pain, ankle sprains, heel pain, non-healing wounds, plantar
fasciitis, poor circulation, diabetic neuropathy, and many other
conditions, as cited in the Journal of Orthopaedic Research (Jan. 2006).
Recently, PRP therapy has made headlines due to its successful use by
professional athletes like Tiger Woods, Kobe Bryant, Alex Rodriguez, and
Rafael Nadal.
http://www.prweb.com/releases/2013/10/prweb11201532.htm